SI2026832T1 - Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis - Google Patents
Combination of interferon-beta and a cladribine regimen for treating multiple sclerosisInfo
- Publication number
- SI2026832T1 SI2026832T1 SI200730939T SI200730939T SI2026832T1 SI 2026832 T1 SI2026832 T1 SI 2026832T1 SI 200730939 T SI200730939 T SI 200730939T SI 200730939 T SI200730939 T SI 200730939T SI 2026832 T1 SI2026832 T1 SI 2026832T1
- Authority
- SI
- Slovenia
- Prior art keywords
- multiple sclerosis
- interferon
- beta
- combination
- treating multiple
- Prior art date
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title abstract 2
- 102000003996 Interferon-beta Human genes 0.000 title abstract 2
- 108090000467 Interferon-beta Proteins 0.000 title abstract 2
- 229960002436 cladribine Drugs 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 229960001388 interferon-beta Drugs 0.000 title 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06114537 | 2006-05-24 | ||
| US84547006P | 2006-09-18 | 2006-09-18 | |
| EP07729448A EP2026832B1 (en) | 2006-05-24 | 2007-05-23 | Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis |
| PCT/EP2007/055013 WO2007135172A2 (en) | 2006-05-24 | 2007-05-23 | Cladribine regimen for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2026832T1 true SI2026832T1 (en) | 2012-07-31 |
Family
ID=37395884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200730939T SI2026832T1 (en) | 2006-05-24 | 2007-05-23 | Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis |
Country Status (12)
| Country | Link |
|---|---|
| CN (1) | CN101500598A (en) |
| AT (1) | ATE555804T1 (en) |
| BR (1) | BRPI0710326A2 (en) |
| DK (1) | DK2026832T3 (en) |
| EC (1) | ECSP088997A (en) |
| ES (1) | ES2384399T3 (en) |
| MY (1) | MY149042A (en) |
| NZ (1) | NZ572680A (en) |
| PT (1) | PT2026832E (en) |
| RS (1) | RS52424B (en) |
| SI (1) | SI2026832T1 (en) |
| UA (1) | UA96941C2 (en) |
-
2007
- 2007-05-23 UA UAA200813662A patent/UA96941C2/en unknown
- 2007-05-23 CN CNA2007800178290A patent/CN101500598A/en active Pending
- 2007-05-23 PT PT07729448T patent/PT2026832E/en unknown
- 2007-05-23 MY MYPI20084741A patent/MY149042A/en unknown
- 2007-05-23 ES ES07729448T patent/ES2384399T3/en active Active
- 2007-05-23 AT AT07729448T patent/ATE555804T1/en active
- 2007-05-23 NZ NZ572680A patent/NZ572680A/en unknown
- 2007-05-23 BR BRPI0710326-3A patent/BRPI0710326A2/en not_active IP Right Cessation
- 2007-05-23 SI SI200730939T patent/SI2026832T1/en unknown
- 2007-05-23 RS RS20120252A patent/RS52424B/en unknown
- 2007-05-23 DK DK07729448.6T patent/DK2026832T3/en active
-
2008
- 2008-12-19 EC EC2008008997A patent/ECSP088997A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101500598A (en) | 2009-08-05 |
| BRPI0710326A2 (en) | 2011-08-09 |
| ES2384399T3 (en) | 2012-07-04 |
| RS52424B (en) | 2013-02-28 |
| UA96941C2 (en) | 2011-12-26 |
| MY149042A (en) | 2013-07-15 |
| ECSP088997A (en) | 2009-01-30 |
| PT2026832E (en) | 2012-06-01 |
| DK2026832T3 (en) | 2012-06-25 |
| NZ572680A (en) | 2011-11-25 |
| ATE555804T1 (en) | 2012-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007135172A3 (en) | Cladribine regimen for treating multiple sclerosis | |
| PH12014502847A1 (en) | Combination treatment (eg with abt-072-333) of daas for use in treating hcv | |
| PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
| ZA200807879B (en) | Use of bifidobacterium longum for the prevention and treatment of inflammation | |
| NZ604031A (en) | Methods of treatment of pancreatic cancer | |
| MY162067A (en) | Combination therapy for treatment of patients with neurological disorders and cerebral infarction | |
| PL2219642T3 (en) | Silibinin component for the treatment of hepatitis | |
| PH12013501791A1 (en) | Uses of dpp~iv inhibitors | |
| UA106756C2 (en) | genetic markers associated with response to interferon alpha | |
| TW200630093A (en) | Dose forms | |
| TN2011000176A1 (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | |
| MY204500A (en) | Dosing regimen associated with long acting injectable paliperidone esters | |
| MX2008013304A (en) | Glp-1 compounds. | |
| MX2014002555A (en) | A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate. | |
| MX2009012598A (en) | Dose forms comprising vx- 950 and their dosage regimen. | |
| WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
| MX2009003532A (en) | Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin. | |
| NZ705124A (en) | Interferon-beta for use as monotherapy or in combination with other cancer therapies | |
| MX2009001433A (en) | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy. | |
| IL205452A (en) | Antagonists of type i interferon (ifn) and their use in the manufacture of medicaments for treating scleroderma | |
| RS52424B (en) | Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis | |
| AR077460A1 (en) | USE OF THE COMBINATION OF TERIFLUNOMIDE AND INTERFERON BETA FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| UA41629U (en) | Method for treating chronic toxoplasma infection | |
| MY174803A (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | |
| UA99163C2 (en) | Dosing regimen associated with long acting injectable paliperidone esters |